Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Cost Reimbursement
Drugs
Locations
Clinical Specialty
321-340 of 991 trials

Generalized Myasthenia Gravis: Iptacopan Study

We are studying a new treatment called iptacopan for people with generalized Myasthenia Gravis to see if it helps improve daily activities and muscle strength. The trial will also assess the safety of this treatment compared to a placebo.

AChR Myasthenia Gravis6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementInternal MedicineNeurology

Autoimmune Cytopenias: Povetacicept Study

We are testing a new treatment called povetacicept for individuals with autoimmune cytopenias. The study aims to evaluate its safety and effectiveness in managing this condition.

Autoimmune Cytopenias6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematologyInfectious Diseases

Chronic Immune Thrombocytopenia: Kedrion IVIg Treatment

We are studying a new intravenous treatment for adults with chronic immune thrombocytopenia to see if it can increase platelet counts and reduce bleeding. This trial will help us understand how well this treatment works and its safety.

Chronic Immune Thrombocytopenia≤3 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematology

Melanoma Treatment: Daromun Injection Study

We are studying whether intratumoral injections of Daromun can help patients with Stage IIIB/C melanoma live longer and reduce the chance of cancer returning after surgery. This trial compares the new treatment to standard surgery and therapy.

Stage III Superficial Spreading Melanoma>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementDermatologyOncology

Breast Cancer: Vepdegestrant and Samuraciclib Study

We are investigating the safety and effectiveness of a new oral medication combined with another treatment for adults with advanced or metastatic hormone receptor-positive breast cancer. This study aims to find better treatment options for patients facing this condition.

Advanced Breast CancerSafety phase (I)Efficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Scleroderma-Related Lung Disease: Investigational Treatments

We are studying new treatments for interstitial lung disease in people with scleroderma to see if they improve lung function and overall health compared to a placebo.

Interstitial Lung Disease due to Systemic Sclerosis1-2 yearsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemotePulmonologyRheumatology

Non-Small Cell Lung Cancer: Divarasib with Other Therapies

We are studying the safety and effectiveness of divarasib combined with pembrolizumab and chemotherapy in patients with untreated advanced lung cancer that has a KRAS G12C mutation. This research aims to find the best dose and treatment approach.

Non-Small Cell Lung Cancer>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology

Zilovertamab Vedotin for Pediatric Cancers

We are studying a new treatment for children and young adults with blood cancers and solid tumors. The trial aims to assess its safety and how well it may work in these young patients.

Blood Cancers and Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncologyPediatrics

Plaque Psoriasis: ESK-001 Treatment Study

We are testing a new medication, ESK-001, for people with moderate to severe plaque psoriasis. The study aims to see if it works better than a placebo and an existing treatment.

Moderate to Severe Plaque Psoriasis6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementDermatology

Upper Limb Spasticity: New Botulinum Toxin Treatment

We are investigating a new injection for adults with upper limb spasticity to see if it is safe and effective compared to existing treatments. This study will help us understand how well it works over time.

Upper Limb Spasticity1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementNeurologyOrthopedics and Traumatology

Familial Hypercholesterolemia: Inclisiran Safety Study

We are studying the long-term safety and tolerability of inclisiran in individuals with familial hypercholesterolemia who have completed earlier studies. This research aims to understand how well the treatment works over time.

Familial Hypercholesterolemia>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

ACP-204 for Alzheimer's Disease Psychosis

We are testing the effects of ACP-204 in adults with Alzheimer's disease psychosis to see if it helps improve symptoms compared to a placebo.

Alzheimer's DiseaseAlzheimer's Disease Psychosis3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPsychiatry

HER2-Low Metastatic Breast Cancer: DB-1303 vs Chemotherapy

We are studying a new treatment, DB-1303, for patients with HER2-low, hormone receptor-positive metastatic breast cancer. The goal is to see if it works better than standard chemotherapy after previous treatments have failed.

Hormone Receptor Positive Breast Cancer1-2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Ongoing Treatment with Durvalumab for Cancer Patients

We are providing continued treatment for patients who have benefited from Durvalumab in a previous study. The focus is on monitoring safety and tolerability during this ongoing care.

Advanced Non-Small Cell Lung CancerPost-Chemotherapy Urothelial CarcinomaExtensive Stage Small-Cell Lung Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

COVID-19 Vaccine: Preventing Type 1 Diabetes in At-Risk Children

We are studying if vaccinating children with a higher genetic risk for type 1 diabetes against COVID-19 can lower their chances of developing diabetes and related autoimmune conditions. This research aims to see if the vaccine can help protect their health.

Risk for Type 1 Diabetes>2 yearsMonitoring phase (IV)11-15 visitsStandard MedicinesCost ReimbursementEndocrinologyInfectious Diseases

Alzheimer's Disease Psychosis: ACP-204 Study

We are examining the long-term safety and tolerability of ACP-204 in adults with Alzheimer's Disease Psychosis. This study helps us understand how well patients can handle this treatment over time.

Alzheimer's Disease Psychosis1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Pulmonary Fibrosis: Long-Term Study of BI 1015550

We are investigating the long-term safety and effectiveness of BI 1015550 in patients with pulmonary fibrosis who have previously participated in related studies. This study aims to understand how well the treatment is tolerated and its potential benefits.

Idiopathic Pulmonary FibrosisProgressive Pulmonary Fibrosis>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemotePulmonology

Generalized Myasthenia Gravis: Efgartigimod Safety Study

We are studying the safety of efgartigimod given through IV and injection in children with generalized myasthenia gravis. This trial aims to ensure the treatment is safe and well-tolerated.

Myasthenia GravisEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Thalassemia and Myelodysplastic Syndromes: SP-420 Treatment Study

We are investigating a new treatment, SP-420, for individuals with transfusion-dependent thalassemia or low-risk myelodysplastic syndromes. The study aims to find the right dose and evaluate its effectiveness in reducing excess iron and its safety.

Thalassemia and Myelodysplastic Syndromes6-12 monthsEfficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementHematology

Zolpidem Responses: Understanding Effects in Different Patients

We are investigating how zolpidem affects people with disorders of consciousness, vision impairments, and healthy volunteers. This study aims to uncover why some individuals respond differently to the medication.

Vision ImpairmentsDisorders of ConsciousnessHealthy Volunteers≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementInternal MedicineNeurologyPsychiatry